The aim of this document is to provide guidance to Health Professionals on the management of rashes in pregnancy and when serological tests should and should not be offered in pregnancy and which tests may be relevant following specific ultrasound findings.
July 2022 - Revision to Section 3.3 ChickenPox (Varicella Zoster Virus) of this document. Please note the recommended post exposure prophylaxis for susceptible individuals is antivirals except for neonates exposed within one week of delivery (either in utero or post-delivery) for whom VZIG continues to be offered -please see Guidelines on post exposure prophylaxis (PEP) for varicella/shingles (April 2022)
ASW will be reviewing and updating this document Autumn-Winter 2022.
There are separate protocols and factsheets available for HIV reactive, Hepatitis B reactive and Syphilis reactive management.
There is an information for women leaflet, Communicable Disease Reactive Results in Pregnancy, to be provided to the woman at the same time as the result is discussed.
As agreed by the UK NSC and Welsh Government the antenatal screening programme for rubella susceptibility screening stopped in Wales on 3 October 2016.
The frequently asked questions have been developed for use when giving information to women around the cessation of rubella screening.
There is also a version developed specifically for women which can be found on the Antenatal Screening Wales public website.